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Salivary melatonin in oral 
squamous cell carcinoma patients
Ivan Salarić1,2,6, Ivana Karmelić3,6, Jasna Lovrić3, Ksenija Baždarić4, Marko Rožman5, 
Igor Čvrljević2, Ivan Zajc1,2, Davor Brajdić1,2 & Darko Macan1,2*
Melatonin’s role in circadian rhythm is well documented, as are its’ anti-oxidant, oncostatic and anti-
inflammatory properties. Poor sleep quality has been associated as a potential risk factor for several 
malignancies, including head and neck cancers. The purpose of this study is to determine salivary 
melatonin (MLT) levels in oral squamous cell carcinoma (OSCC) patients, compare the salivary MLT 
levels with those in healthy individuals and compare the salivary and serum levels in OSCC patients. 
Furthermore, the aim is to investigate the potential relationship between sleep quality and salivary 
MLT levels in OSCC patients. Unstimulated (UWS) and stimulated (SWS) whole saliva was sampled 
from patients with T1N0M0 and T2N0M0 OSCC (N = 34) and 33 sex and age matched healthy subjects. 
Serum samples were taken from 11 OSCC patients. Sleep quality was measured using Pittsburgh Sleep 
Quality Index (PSQI) questionnaire. Melatonin levels in UWS and SWS were significantly higher in the 
OSCC group. Sleep quality was significantly lower in patients with OSCC (P = 0.0001). ROC analysis 
was found to be significant (P < 0.001) in evaluating MLT concentration limit in diagnosing OSCC. 
The expected relationship between sleep quality and salivary MLT levels in OSCC patients was not 
observed. Our results suggest salivary MLT as a potential biomarker that might facilitate non-invasive 
detection of early stage OSCC.
More than 325,000 people worldwide die from head and neck cancers every  year1,2. Oral squamous cell carcinoma 
(OSCC) makes up nearly 55% of all head and neck cancers and has a 60% 5-year survival  rate1,2. Tobacco and 
alcohol consumption are long known risk habits for OSCC development. Unfortunately, this disease is often 
diagnosed in the advanced stage and tissue histopathological examination is still considered as a gold standard 
for OSCC diagnosis. A number of studies identified potential salivary, tissue, plasma and serum biomarkers for 
OSCC, but unfortunately, none of the suggested biomarkers are in clinical  use3–6. Apart from diagnostics, search 
for biomarkers may contribute towards a better understanding of OSCC carcinogenesis.
Recently, several cancer research studies focused on melatonin (N-acetyl-5-methoxytryptamine) (MLT) due 
to its’ anti-oxidant, oncostatic and anti-inflammatory  properties7–10. Melatonin’s role in circadian rhythm is well 
documented and sleep deprivation has been associated with head and neck, breast, prostate and other  cancers11–13. 
In vitro studies reported growth reduction in different types of cancer due to MLT oncostatic and anti-oxidant 
 properties14–16. However, studies on serum MLT levels in different types of cancer patients have yielded conflicting 
results. Decreased serum MLT levels have been registered in patients with breast cancer, prostate cancer, lung 
cancer, stomach and colon  cancer17–20. One of the suggested explanations for this was decreased sleep quality 
and increased fatigue in cancer  patients18,20. Thereby, decreased sleep quality would result in the aberrant MLT 
synthesis during night-time and the overall MLT circadian rhythm. On the other hand, several papers have reg-
istered elevated serum MLT levels in colorectal carcinoma, melanoma and multiple  myeloma21–23. These results 
have been explained by a reaction to cellular damage and a protective mechanism i.e. the overproduction of MLT 
for the purpose of stimulating the immune system and scavenging the free radicals. The exact mechanism and 
the role of the impaired MLT secretion in carcinogenesis of these malignancies remains unclear.
The role of MLT in OSCC has been investigated in several papers. Lu et al.24 and Yeh et al.25 showed that 
MLT represses OSCC metastasis. Yang et al. revealed the beneficial effect of MLT in the reduction of OSCC 
 proliferation26. Stanciu et al.27 measured serum MLT levels in patients with OSCC and presented a clinical pre-
dictive model for the severity of OSCC. They obtained lower serum MLT levels in OSCC patients compared to 
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healthy individuals and suggested a negative correlation between MLT serum levels and the severity of OSCC 
stages.
Due to its’ proximity to cancer cells and non-invasive sampling, saliva as a diagnostic fluid has its’ clear ben-
efits in OSCC biomarker and carcinogenesis research. Furthermore, it is less expensive and more accessible than 
tissue, serum or plasma sampling. Recent studies found matrix metallopeptidase 2 (MMP2) and 9 (MMP9), Cyfra 
21-1, tissue polypetide antigen (TPA), cancer antigen CA-125 and tumour necrosis factor α (TNF-α), interleukin 
8 (IL-8) and IL-1β elevated in the saliva of OSCC  patients28,29.
According to the available literature, salivary MLT levels in OSCC patients have not yet been measured. The 
aim of this research is to measure MLT in unstimulated whole saliva (UWS) and stimulated whole saliva (SWS) 
in OSCC patients and to compare the salivary and serum MLT levels in OSCC patients. Furthermore, the aim 
is to assess respondents’ sleep quality using the Pittsburgh Sleep Quality Index (PSQI) in order to observe the 
possible causal link with salivary MLT levels.
Results
Thirty-four OSCC patients and 33 healthy individuals were included in this study, out of which 48 were male 
(71.6%) and 19 female (28.4%) (Table 1). There was no statistical difference in age (t = 0.793; P = 0.43) and sex 
(χ2 = 0.12, P = 0.730) distribution between groups. We report no missing data since none of the subjects had 
refused to participate or quit during the experiment and since all specimens were successfully analysed.
Alcohol consumption between groups differed significantly (χ2 = 13.10; P = 0.004). More patients in the 
experimental group consumed over 5 alcohol units than those in the control group (t test proportion P = 0.046). 
The distribution of respondents with respect to tobacco consumption did not differ significantly between groups 
(χ2 = 0.12; P = 0.73). However, a significantly higher number of cigarettes was consumed by the experimental 
group (OSCC) (χ2 = 19.61; P = 0.0015) (Table 1).
Most common OSCC localisation was the body and the apex of the tongue (N = 16 (47.06%)), followed by the 
sublingual region and the mandibular gingiva (both N = 5 (14.71%)), retromolar region in the lower jaw and the 
maxillary gingiva (both N = 3 (8.82%)), cheek and the hard palate (both N = 1 (2.94%)). Twelve out of 16 tongue 
OSCC were staged as T2N0M0, along with 3 out of 5 sublingual, two out of 5 located in the mandibular gingiva, 
one out of 3 in the retromolar region of the mandible and maxillary gingiva and the one on the hard palate. The 
rest of the OSCC were T1N0M0.
Melatonin concentrations in UWS and SWS were significantly higher in the OSCC group compared to the 
control group (Table 2; Fig. 1). Furthermore, MLT levels were higher in the UWS than in SWS both in the control 
[Mann Whitney’s U test value (U) = 178.50; P < 0.0001] and the OSCC group (U = 263.50; P = 0.0002). When 
observing the OSCC subgroups, significant difference was found between patients with T1N0MO and T2N0M0 
OSCC and the control group in the UWS and SWS (Table 3).
No statistically significant difference in MLT levels was obtained between patients with T1N0M0 and 
T20N0M0 OSCC in UWS (U = 107.00; P = 0.248) and SWS (U = 103.00; P = 0.195) (Supplement 1).
Median value for serum MLT in OSCC patients (N = 11) was 13.01 (95% CI 10.08–15.14) (Table 2). Median 
ratios between MLT in UWS and serum MLT and MLT in SWS and serum MLT amounted to 23.66% and 
13.15%, respectively.
Table 1.  Oral squamous cell carcinoma (OSCC) group and control group description. a OSCC oral squamous 
cell carcinoma, SD standard deviation, a.u. alcohol unit, cig. cigarettes.
OSCC group (N = 34) Control group (N = 33) Statistics
Age (mean ± SD) 60.6 ± 11.1 63.0 ± 13.3 t = 0.793;P = 0.43
Sex (male (%)/female (%)) 25 (73.53%)/9 (26.47%) 23 (69.70%)/10 (30.30%) χ
2 = 0.12;
P = 0.73
T1N0M0 14 (41.18%) – –
T2N0M0 20 (58.82%) – –
Only smoked 5 (14.71%) 13 (39.40%) χ
2 = 5.12;
P = 0.02
Only consumed alcohol 5 (14.71%) 5 (15.15%) χ
2 = 0.003;
P = 0.96
Consumed alcohol and smoked 14 (41.18%) 1 (3.03%) P = 0.0002
Alcohol altogether
Does not drink: 4 (11.76%)
1 a.u./day: 10 (29.41%)
2–4 a.u./day: 9 (26.47%)
 > 5a.u./day: 11 (32.35%)
Does not drink: 14 (42.42%)
1 a.u./day: 12 (36.36%)
2–4 a.u./day: 5 (15.15%)




Does not smoke:14 (41.18%)
1–5 cig./day: 3 (8.82%)
6–10 cig./day: 1 (2.94%)
11–20 cig./day: 3 (8.82%)
21–35 cig./day: 9 (26.47%)
 > 36 cig./day: 4 (11.76%)
Does not smoke:15 (45.45%)
1–5 cig./day: 4 (12.12%)
6–10 cig./day: 8 (24.24%)
11–20 cig./day: 6 (18.18%)
21–35 cig./day: 0 (0%)
 > 36 cig./day: 0 (0%)
χ2 = 0.12;
P = 0.73
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Sleep quality was significantly lower, i.e. PSQI was significantly higher in OSCC patients than in the control 
group [median (95% CI) 4 (3–5) vs. 6 (5–8); U = 249.50; P = 0.0001] (Fig. 2).
Respondents’ systemic diseases and conditions indexed by ICD-11 and drug consumption indexed by ATC 
are presented in the Supplement 2 and 3.
ROC analysis was found to be significant (P < 0.001) in evaluating the MLT concentration limit in diagnosing 
OSCC. The area under the curve amounted to 0.84, with a sensitivity of 97.1% (95% CI 84.7–99.9), specificity 
of 57.6% (95% CI 39.2–74.5) and the MLT concentration limit in UWS of 0.835 pg/ml (Youden Index: 0.546) 
Table 2.  Melatonin levels comparison in unstimulated and stimulated whole saliva between the groups 
and descriptive statistics for melatonin serum values in oral squamous cell carcinoma patients. a OSCC oral 
squamous cell carcinoma, CI confidence interval, UWS unstimulated whole saliva, SWS stimulated whole 












Minimal value (pg/ml) 0.52 0.10b=2 0.10b=1 0.10b=5 6.16
Maximal value (pg/ml) 18.98 6.31 13.91 3.40 27.16
Median (95% CI) 3.08 (2.31–4.47) 0.66 (0.44–1.52) 1.71 (0.91–2.61) 0.57 (0.10–1.02) 13.01 (10.08–15.14)
Interquartile range 1.71–4.97 0.35–1.80 0.85–4.53 0.10–1.27 –
Statistics U = 178.50 P < 0.001 U = 263.50 P < 0.001 –
Figure 1.  Comparison of salivary melatonin levels (pg/ml) in unstimulated whole saliva (UWS) and stimulated 
whole saliva (SWS) between the oral squamous cell carcinoma (OSCC) and the control group expressed with 
median and 95% confidence interval for the median.
Table 3.  Melatonin levels comparison in unstimulated and stimulated whole saliva between oral squamous 
cell carcinoma subgroups and control group. a OSCC oral squamous cell carcinoma, CI confidence interval, 

















UWS SWS UWS SWS
Minimal value 
(pg/ml) 1.12 0.10
b=2 0.10 0.10b=5 0.52 0.10b=2 0.10b=1 0.10b=5
Maximal value 
(pg/ml) 10.71 6.31 13.91 3.40 18.98 6.31 13.54 3.40
Median (95% CI) 3.67 (2.36–5.29) 0.66 (0.44–1.52) 2.42 (0.86–6.22) 0.57 (0.10–1.02) 2.73 (1.57–4.66) 0.66 (0.44–1.52) 1.24 (0.83–2.14) 0.57 (0.10–1.02)
Interquartile range 2.39–4.96 0.35–1.80 0.87–6.04 0.10–1.27 1.52–5.39 0.35–1.80 0.80–2.46 0.10–1.27
Statistics U = 50.50; P < 0.0001 U = 81.50; P = 0.0004 U = 128,00; P = 0.0002 U = 182.00; P = 0.006
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(Fig. 3). ROC analysis for distinguishing patients with OSCC from healthy individuals based on values in SWS 
is presented in Supplement 4. ROC analyses for distinguishing patients with T1N0M0 and T2N0M0 OSCC from 
healthy individuals by MLT levels in UWS are presented in the Supplement 5–8. Comparison of OSCC patients 
and the control group determined by the cut off values of MLT levels in UWS (Fig. 3) and SWS (Supplement 4) 
is presented in Supplement 9 and 10, and found statistically significant (Fisher exact test, P < 0.001 and P < 0.001 
respectively).
Discussion
Significantly higher salivary MLT levels were registered in OSCC patients than in healthy subjects. Till this day, 
not all sources of MLT in saliva are known. Potential synthesis inside the salivary glands has been hypothesized by 
several  authors30,31. The concentration of salivary MLT in healthy individuals varies from 1 to 5 pg/ml during day-
time and from 10 to 50 pg/ml during  nightime32,33. Approximately 70% of serum MLT is partially bound to serum 
 albumin32,33. It is considered that only unbounded MLT enters the saliva by passive diffusion from serum to the 
salivary glands, where the MLT concentration reaches up to 33% of the value of MLT serum  concentration33. 
Several papers revealed a receptor-dependant transport and storage of MLT inside the parotid  glands30,34.
Figure 2.  Pittsburgh sleep quality index (PSQI) comparison between the oral squamous cell carcinoma patients 
(OSCC) and the control group expressed with median and 95% confidence interval for the median.
Figure 3.  The receiver operating characteristic curve (ROC) for distinguishing patients with oral squamous 
cell carcinoma from healthy individuals based on values in unstimulated whole saliva (UWS) (AUC area under 
curve; blue line—melatonin (pg/ml); red line—reference line).
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Studies on melatonin receptors 1A (MTNR1A) and squamous cell carcinomas in vitro had revealed dimin-
ished or even non-existent expression of these receptors due to DNA  methylation35. Nakamura et al. have sug-
gested MTNR1A as a target for epigenetic silencing at loci 4q35 which may present one of the key events in oral 
 cancerogenesis36. In vitro, cessation of squamous cell carcinoma growth that lacked the expression of MTNR1A 
was achieved by exogenous restoration of MTNR1A  receptors36.
A possible explanation for elevated salivary MLT levels in OSCC patients could be the MLT receptors disorder 
in OSCC tissue and thereby the insensitivity of OSCC cells to MLT. This hypothesis could imply the protec-
tive direct effect of MLT on healthy oral mucosa, MLT overexpression, insensitivity or decreased expression of 
MTNR1A, but also the possibility of a yet unknown signal pathway. However, research on the expression of MLT 
receptors in vivo in OSCC tissue and clinically unchanged oral mucosa tissue in individuals with OSCC is called 
for to approve or disapprove these hypotheses.
Higher MLT values were registered in UWS than in SWS in both groups (Table 2) and thereby UWS could 
be considered as more representable for research on salivary MLT levels. We are unfamiliar with the reason for 
higher MLT levels obtained in UWS than in SWS, however it is established that over 65% of UWS is composed 
from the submandibular gland saliva and only 20% of the parotic saliva. Stimulated whole saliva is mostly com-
posed from serous parotid gland saliva (> 50%)37. Therefore, we can hypothesize higher MLT concentrations in 
the submandibular than in the parotic saliva.
Serum samples were taken to determine the relationship between the serum and salivary MLT levels in 
OSCC patients and to compare the serum MLT levels in OSCC patients with the reference serum MLT levels in 
healthy population available in literature. Median ratios between MLT in UWS and serum MLT and MLT in SWS 
and serum MLT amounted to 23.66% and 13.15%, respectively. These results are consistent with the expected 
deviation between serum and salivary MLT levels in healthy individuals and do not support or disapprove the 
hypothesis of MLT synthesis in salivary glands. Serum MLT levels in healthy individuals start to increase between 
6 and 8 p.m. and reach the highest values between midnight and 5 a.m., after which they begin to decrease 
 significantly38,39. Between 7 and 9 a.m. MLT levels in serum amount from 7 to 20 pg/ml38–41. Those values do not 
statistically differ from our measurement of serum MLT levels in OSCC patients (median (95% CI): 13.01 pg/ml 
(10.08–15.14), suggesting that serum MLT concentration may not discriminate patients with early stages OSCC. 
Obtained interquartile ranges of serum MLT concentrations overlap with those obtained by Stanciu et al. (18.2 
(11.0–39.2)27. Furthermore, Stanciu et al. suggested that serum MLT concentrations may discriminate patients 
with OSCC with T-DOI II (depth of invasion) (T > 4 cm; DOI > 10 mm) from healthy controls, due to observed 
high serum MLT levels obtained in the healthy control group (median 47.6 pg/ml; interquartile range 37.7–66.4; 
age 57 ± 7 years of age). The serum MLT values below 38.9 pg/ml sampled at 7 a.m. were furthermore identified 
as values with higher risk for OSCC incidence, with a specificity of 75% and sensitivity of 76.6%. Their measure-
ments, however, are inconsistent with other studies on serum MLT levels with healthy subjects older than  fifty38,39 
and rather correlate with the nocturnal serum levels of MLT in healthy  subjects40,42–44.
As expected, the PSQI was significantly higher in OSCC patients than in the control group [median (95% 
CI) 4 (3–5) vs. 6 (5–8); U = 249.50, P = 0.0001]. High PSQI did not correlate with serum and salivary MLT 
values, i.e. we expected lower MLT values in individuals with poor sleep quality, as is the case with some other 
 malignancies11–13. The results of this study cannot justify or refute the exogenous MLT intake for sleep improve-
ment. A bigger sample could provide more information on the connection between serum MLT levels and 
sleep quality in OSCC patients. Given that the salivary MLT concentrations were unknown in OSCC patients, it 
would not have been a mistake to include subjects with metastatic disease and not only T1N0M0 and T2N0M0 
OSCC. However, stratification certainly contributed to the uniformity of this research and could pose potential 
relevance for future research on this topic. Stanciu et al. obtained statistically significant difference between 
OSCC patients with and without nodal  metastasis27. Patients with nodal metastasis had lower MLT values than 
the ones without nodal metastasis. The authors explained this result by the endocrine involvement in the OSCC 
progression, possibly suggesting the disturbed circadian MLT rhythm in patients with nodal metastasis. We found 
no statistically significant difference in salivary MLT levels in UWS and SWS between patients with T1N0M0 
and T2N0M0 OSCC, but it is noticeable that slightly higher levels of MLT, both in UWS [median (95% CI) 3.67 
(2.36–5.29) vs. 2.73 (1.57–4.66)) and SWS (median (95% CI): 2.42 (0.86–6.22) vs. 1.24 (0.83–2.14)], were detected 
in T1N0M0 patients. Stanciu et al. also detected higher serum MLT values in T-DOI I (T ≤ 4 cm; DOI ≤ 10 mm) 
than in T-DOI II (T > 4 cm; DOI > 10 mm)27. It would thereby be intriguing to investigate and compare salivary 
MLT levels in patients with potentially malignant oral disorders and OSCC with and without metastatic disease. 
ROC analysis was performed and found significant (P < 0.001) for the assessment of the salivary MLT concentra-
tion limit in OSCC diagnosis. The area under the curve (AUC) amounted 0.84 and the sensitivity of 97.1% and 
specificity of 57.6% were obtained with an MLT concentration cut-off in the UWS of 0.83 (Youden index: 0.55). 
The results obtained with ROC analysis are even more representative than some of the presented cumulative 
biomarkers for OSCC, such as CEA (carcinoembryonic antigen), SCCA (squamous cell carcinoma antigen) and 
IAP (immunosuppressive acidic protein)45.
Given the AUC value, salivary MLT could present a satisfactory diagnostic tool for OSCC as a tumour bio-
marker alone or in along with some other molecules, such as kininogen 1, cathepsin V, kallikrein 5 or matrix 
metalloproteinase  146–48. However, larger prospective studies are needed to evaluate the clinical use of salivary 
MLT as an OSCC biomarker.
This study has several limitations. Due to the sample size, the correlation between alcohol consumption, 
smoking, particular systemic disease or a drug and the salivary MLT levels could not have been adequately 
assessed. Thereby, the aforementioned could represent potential confounders. Even though squamous cell car-
cinomas located on the tongue root, epiglottis or oropharynx were not included in this study, which are more 
commonly associated with HPV infection, unknown HPV status could present a confounder. The debate in 
literature on whether HPV infections have the same role in OSCC as in oropharyngeal squamous cell carcinoma 
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is still active. PSQI questionnaire has its drawbacks, as does every survey: the inability to create a fully credible 
clinical picture, questionable credibility of the testimony and the recall bias.
Determining salivary MLT using ELISA surely has its’ disadvantages, as the possible effect of the plasma 
constituents from the crevicular fluid and numerous other factors that can influence on the dynamics of serum 
melatonin levels, such as alcohol and nonsteroidal anti-inflammatory drugs (NSAID) consumption, light expo-
sure, sleep quality and other. Although it is difficult to achieve completely objective preconditions for adequate 
determination of salivary MLT using ELISA, especially in the single time point, the authors believe that the 
experimental design and the inclusion criteria for both groups were appropriately rigorous. Mistakes during 
ELISA sampling are common, but trackable, as the testing is performed in duplicate. High viscosity of certain 
salivary samples and its rheological properties can present a problem when analysing samples, even after cen-
trifugation, when it is necessary to separate the supernatant from the precipitate. This technical research problem 
was solved by repeated centrifugation under the same conditions.
We used ROC analysis to evaluate the cut off values of MLT for OSCC diagnosis and to calculate sensitivity 
and specificity. However, as this is a cross-sectional study and as we have not evaluated patients’ survival time, 
prognostic value of MLT in OSCC patients could not have been determined. Therefore, this presents a study 
limitation.
In conclusion, this study revealed elevated salivary MLT levels in patients with T1N0M0 and T2N0M0 OSCC 
compared to healthy subjects. Sleep quality in OSCC patients was worse than in the control group, however, the 
expected correlation between salivary MLT levels and sleep quality was not observed in these patients.
Methods
Subjects and samples. A cross-sectional study was conducted that involved the experimental (OSCC 
group) and the control group. Experimental group consisted of patients with histologically verified T1N0M0 
and T2N0M0 OSCC, in accordance with the 8th edition of the American Joint Cancer Committee on oral cancer 
 staging49, recruited from the Department of Oral and Maxillofacial Surgery, University Hospital Dubrava from 
January 2017 till November 2019. Respondents with OSCC located on the tongue root and epiglottis were not 
included in this study. Biopsy was performed at least two weeks before saliva and serum sampling. None of the 
subjects from the experimental group had received any kind of treatment prior to saliva and serum sampling.
Control group consisted of healthy sex and age matched subjects that attended the Department for a routine 
examination or a tooth extraction. None of the OSCC patients were hospitalized prior to sampling.
Inclusion criteria for both groups were:
• Abstinence from food and beverages at least 8 h before sampling
• Subjects did not take any NSAID at least 24 h before  sampling50
• Subjects did not brush their teeth or rinse their mouths with a mouthwash at least 1 h before sampling
• Subjects did not consume alcoholic beverages at least 24 h prior to  sampling51
• Absence of salivary, jaw and oral mucosal tissue diseases and conditions
• No history of radiation therapy of the head and neck
Saliva and serum sampling. Saliva and serum were sampled before any surgical procedure between 7 
and 9 a.m. in a dark room (< 3 lx). All samples were obtained in the same conditions and by using the specially 
designed saliva collecting  apparatus52. Unstimulated and stimulated saliva samples were obtained from every 
subject. Saliva stimulation was performed by chewing the paraffin blocks. Every saliva sample was stored at 
– 80 °C until the Enzyme-Linked Immuno-Sorbent Assay (ELISA) testing. The processing of frozen saliva sam-
ples and further handling followed the instructions of the ELISA kit manufacturer (IBL International GmbH, 
Hamburg, Germany). ELISA analysis was performed at the Department of Chemistry and Biochemistry at the 
University of Zagreb, School of Medicine, from December 2017 till December 2019.
Manufacturer’s ELISA MLT saliva kits had a limit of detection of 0.3 pg/ml. For purpose of taking every value 
into account, all values below the limit of detection were registered as 0.1 pg/ml.
A blood sample was taken from OSCC patients during routine blood sampling, immediately after saliva sam-
pling. Blood specimens were centrifuged and afterwards stored at -80˚C until ELISA analysis (IBL International 
GmbH, Hamburg, Germany).
Indices, medical and dental history. Medical and dental history was taken before sampling. Every sub-
ject filled out a Croatian validated version of the Pittsburgh Sleep Quality Index Questionnaire before  sampling53.
Drug consumption was indexed by the Anatomical Therapeutic Chemical Classification System (ATC)54, 
while the systemic conditions were indexed by the International Statistical Classification of Diseases and Related 
Health Problems 11 (ICD-11)55.
OSCC risk habits were classified as alcohol consumption, tobacco consumption, alcohol and tobacco con-
sumption and as no risk habits. Alcohol consumption was registered as the average daily alcohol consumption 
expressed in alcohol units. One alcohol unit (a.u.) consisted of 100 ml of wine, 330 ml of beer or 50 ml of hard 
liquor. Tobacco consumption was registered as the average number of daily smoked cigarettes.
Statistical analysis. Categorical data are shown by frequency and relative frequency and compared using 
the χ2 test. The post-hoc analysis for χ2 test was performed using the t test for proportions. Quantitative data 
are presented as mean and standard deviation and tested with t test for two groups. Average values of variables 
that have non-normal distribution (tested with Kolmogorov–Smirnov test) are presented with median and inter-
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quartile range, and compared using Mann Whitney’s U test. Receiver operating characteristic (ROC) was used 
to evaluate the cut off values of MLT and to calculate sensitivity and specificity. Fisher exact test was used to 
compare the number of patients in the experimental and control group correctly identified with the cut off values 
of MLT in UWS and SWS. The correlation was calculated by Spearman’s nonparametric correlation coefficient. 
Sample size calculation for testing the hypothesis was based on the results of the MLT circadian  values32,37,38. The 
significant sample size was calculated using the G Power 3.1.9.256. Given that the salivary MLT levels in healthy 
individuals amount from 1 to 5 pg/ml between 7 and 9 a.m.32, we expected salivary MLT levels in OSCC patients 
bellow 0.8 pg/ml. With an α = 0.05 and the power of 0.80 the suggested sample size was 12 subjects. Serum MLT 
levels of healthy individuals over 40 years age amount between 7 and 20 pg/ml between 7 and 9 a.m.37,38, thereby 
values bellow 5 pg/ml were expected in OSCC patients. With an α = 0.05 and the power of 0.80 the suggested 
sample size was 9 subjects. Data was collected and stored to the database in MS Excel. Statistical data processing 
was done using the MedCalc ver. 16.2.1. (MedCalc Software, Ostend, Belgium). The level of statistical signifi-
cance was set at 5% (P < 0.05) and all confidence intervals were given at a 95% level.
The study was approved by the Ethics Committee of the School of Dental Medicine, University of Zagreb and 
the University Hospital Dubrava Ethics Committee. All methods were performed in accordance with the relevant 
guidelines and regulations. Written informed consent was obtained from all participants. This manuscript was 
written in accordance with the STROBE recommendations.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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